- US12577588utility2026AAV Capsids with Increased Tropism to Brain Tissue0 cites
- US12467046utility2025Redirection of Tropism of AAV Capsids0 cites
- US12419969utility2025AAV Capsid Variants and Uses Thereof0 cites
- US12319929utility2025Compositions and Methods for the Treatment of Parkinson's Disease0 cites
- US12305189utility2025Compositions and Methods for Delivery of AAV0 cites
- US12296025utility2025AAV Capsid Variants and Uses Thereof0 cites
- US12291565utility2025Tau Binding Compounds0 cites
- US12281321utility2025Frataxin Expression Constructs Having Engineered Promoters and Methods of Use Thereof0 cites
- US12180500utility2024Chimeric Capsids0 cites
- US12129476utility2024Methods for Measuring the Potency of AADC Viral Vectors0 cites
- US12123002utility2024Compositions and Methods of Treating Amyotrophic Lateral Sclerosis (ALS)0 cites
- US12116589utility2024Treatment of Amyotrophic Lateral Sclerosis (ALS)0 cites
- US12084659utility2024Modulatory Polynucleotides0 cites
- US12071625utility2024Modulatory Polynucleotides0 cites
- US12060567utility2024Engineered Untranslated Regions (UTR) for AAV Production0 cites
- US11975056utility2024AADC Polynucleotides for the Treatment of Parkinson's Disease0 cites
- US11951121utility2024Compositions and Methods for Treating Huntington's Disease0 cites
- US11931375utility2024Treatment of Amyotrophic Lateral Sclerosis (ALS)0 cites
- US11859200utility2024AAV Capsids with Increased Tropism to Brain Tissue0 cites
- US11759506utility2023AADC Polynucleotides for the Treatment of Parkinson's Disease0 cites
Page 1 of 2Next →